Sarepta Therapeutics Executive and Leadership Team

Michael Severino, the Chief Executive Officer at Sarepta Therapeutics, directs the overarching corporate strategy and long-term vision for the organization. Overseeing the development of precision genetic medicines, the Chief Executive Officer ensures the company maintains a competitive edge in the biopharmaceutical sector. This leadership role involves managing complex interactions with the Board and investors to secure the resources necessary for scaling the global pipeline. By prioritizing innovation in Duchenne muscular dystrophy and other rare diseases, Michael Severino drives the company toward sustainable growth and market leadership. The Chief Executive Officer also monitors the integration of gene therapy and RNA-targeted platforms across North American and international markets. Through rigorous oversight of the commercial-stage portfolio, Severino guarantees that the organization remains at the forefront of genetic medicine, ultimately delivering transformative treatments to patients worldwide while maximizing shareholder value.

Ian Estepan, the President & Chief Operating Officer at Sarepta Therapeutics, directs the day-to-day business operations and strategic execution of the company's commercial-stage activities. Overseeing the infrastructure required to support the global distribution of genetic medicines, the President & Chief Operating Officer ensures that internal processes scale effectively with the company's growth. This role involves managing the intersection of corporate strategy and operational performance to drive revenue and efficiency. By optimizing the supply chain and commercial operations, Ian Estepan supports the successful delivery of therapies to patients across North America, Europe, and Asia. The President & Chief Operating Officer also collaborates with the executive team to refine the company's business model and market approach. Through rigorous management of operational resources, Estepan ensures that the organization remains agile in the competitive biopharmaceutical landscape, ultimately securing the company's long-term financial stability and its ability to innovate within the precision genetic medicine space.

Louise Rodino-Klapac, the President, Research Development & Technical Operations at Sarepta Therapeutics, directs the scientific discovery and technical manufacturing processes for the company's genetic medicine portfolio. Overseeing the research pipeline and the scaling of technical operations, the President, Research Development & Technical Operations ensures that the company's gene therapy and RNA-targeted platforms meet the highest standards of quality and efficacy. This role involves managing the transition from laboratory research to clinical development and commercial-scale manufacturing. By driving innovation in the development of precision genetic medicines, Louise Rodino-Klapac supports the company's leadership in treating Duchenne muscular dystrophy and other rare disorders. The President, Research Development & Technical Operations also collaborates with regulatory and clinical teams to accelerate the path to market for new therapies. Through rigorous scientific oversight and technical expertise, Rodino-Klapac ensures that the company's research programs remain at the cutting edge of the biopharmaceutical industry, ultimately delivering transformative solutions to patients.

Zohal Ghiaszada, the Senior Director, Chief of Staff To Chief Medical and Regulatory Officer at Sarepta Therapeutics, manages the operational flow and strategic priorities within the medical and regulatory divisions. Coordinating cross-functional initiatives, the Senior Director, Chief of Staff To Chief Medical and Regulatory Officer ensures that clinical development programs align with global regulatory standards. This role involves facilitating communication between the medical leadership and internal teams to accelerate the delivery of genetic therapies. By optimizing internal processes, Zohal Ghiaszada supports the advancement of the company's pipeline across diverse neuromuscular disorders. The Senior Director, Chief of Staff To Chief Medical and Regulatory Officer also monitors the execution of clinical milestones to ensure adherence to strict timelines. Through effective management of departmental resources, Ghiaszada enables the medical team to focus on high-impact research, thereby strengthening the company's position as a leader in the development of precision genetic medicines for rare diseases.

Kirsten Meisterling, the Senior Director, Chief of Staff To Senior Vice President, Medical Affairs at Sarepta Therapeutics, coordinates the strategic operations of the global medical affairs department. Overseeing the alignment of medical initiatives with the company's broader commercial goals, the Senior Director, Chief of Staff To Senior Vice President, Medical Affairs ensures that scientific data effectively supports the adoption of genetic therapies. This role involves managing complex project workflows and facilitating collaboration between medical affairs and research teams. By streamlining internal communications, Kirsten Meisterling drives efficiency across the organization's medical programs. The Senior Director, Chief of Staff To Senior Vice President, Medical Affairs also monitors the impact of medical education and outreach efforts in key global markets. Through meticulous planning and resource allocation, Meisterling supports the successful commercialization of precision medicines, ensuring that the medical affairs function remains agile and responsive to the evolving needs of the rare disease patient community.

Kirsten M., the Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff at Sarepta Therapeutics, architects the operational framework for global medical affairs. Managing the lifecycle of medical programs, the Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff ensures that clinical data dissemination and medical strategy remain synchronized. This role involves overseeing the integration of program management tools to enhance the efficiency of medical operations across international regions. By driving process improvements, Kirsten M. supports the rapid development and commercialization of the company's genetic medicine portfolio. The Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff also coordinates with cross-functional leaders to ensure that medical objectives align with the company's mission. Through strategic oversight of operational workflows, M. enables the medical affairs team to execute complex projects effectively, ultimately contributing to the successful delivery of precision therapies for patients with rare neuromuscular disorders.

William Tilton, the Senior VP, Corporate Strategy & Chief of Staff at Sarepta Therapeutics, architects the long-term strategic planning and organizational alignment for the company. Managing the integration of corporate initiatives, the Senior VP, Corporate Strategy & Chief of Staff ensures that all departments work toward the core mission of advancing precision genetic medicines. This role involves analyzing market trends and competitive dynamics to inform the company's growth trajectory. By facilitating communication between the executive leadership and the broader organization, William Tilton drives the execution of key strategic priorities. The Senior VP, Corporate Strategy & Chief of Staff also oversees the development of internal frameworks that support the company's global operations. Through careful analysis and strategic foresight, Tilton enables the organization to navigate the complexities of the biopharmaceutical industry, ensuring that the company remains focused on its goal of delivering transformative treatments for rare diseases while maintaining operational excellence.

Alison Nasisi, the Executive Vice President & Chief People Officer at Sarepta Therapeutics, directs the human capital strategy and organizational culture for the company. Overseeing talent acquisition, leadership development, and employee engagement, the Executive Vice President & Chief People Officer ensures that the organization attracts and retains the expertise necessary to advance its genetic medicine pipeline. This role involves building a high-performance culture that supports innovation and collaboration across all global locations. By implementing robust HR programs, Alison Nasisi drives the alignment of the workforce with the company's mission to treat rare diseases. The Executive Vice President & Chief People Officer also collaborates with the executive team to foster an inclusive environment that promotes professional growth and operational success. Through strategic management of the company's human resources, Nasisi ensures that the organization remains a top employer in the biopharmaceutical sector, ultimately supporting the company's ability to deliver life-changing therapies to patients.